{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T17:26:52Z","timestamp":1794245212788,"version":"4.9.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012681","name":"Universit\u00e4tsklinikum K\u00f6ln","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012681","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Gastrointestinal cancers account for a substantial share of global cancer burden. We assessed the significance of MTAP loss across 1545 resected tumors (cholangiocarcinoma, esophageal and gastric adenocarcinoma, pancreatic ductal adenocarcinoma). MTAP protein was evaluated by immunohistochemistry compared with CDKN2A status by fluorescence in situ hybridization and with overall survival. Immunohistochemical MTAP loss consistently co-occurred with homozygous CDKN2A deletion and was present in 25.5% of cholangiocarcinomas, 9.3% of esophageal adenocarcinomas, 10.3% of gastric carcinomas, and 30.2% of pancreatic adenocarcinomas. In gastric carcinomas, MTAP loss was associated with worse survival (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.024), particularly in those who underwent primary surgery (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.008). MTAP loss proved to be an independent factor for worse overall survival in patients with gastric adenocarcinoma. 10% of esophageal adenocarcinomas showed intratumoral heterogeneity, but we did not see intertumoral heterogeneity between the primary tumor and corresponding lymph node metastases. These data indicate that a considerable subset of gastrointestinal cancers exhibits MTAP loss, highlight prognostic relevance in gastric carcinoma, and delineate a potentially actionable subgroup for PRMT5 inhibitor therapy.\n                  <\/jats:p>","DOI":"10.1038\/s41598-026-51370-9","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T15:55:30Z","timestamp":1778687730000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["MTAP loss in gastrointestinal cancers is associated with CDKN2A deletion, poor prognosis in gastric carcinoma, and potential relevance for PRMT5-targeted therapy"],"prefix":"10.1038","volume":"16","author":[{"given":"Su Ir","family":"Lyu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Knipper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Fretter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Tzitzili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian Georg","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakan","family":"Alakus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aylin","family":"Pamuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane J.","family":"Bruns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix C.","family":"Popp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Quaas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"issue":"27","key":"51370_CR1","doi-asserted-by":"publisher","first-page":"4298","DOI":"10.3748\/wjg.v27.i27.4298","volume":"27","author":"JX Hu","year":"2021","unstructured":"Hu, J. X. et al. Pancreatic cancer: A review of epidemiology, trend, and risk factors. World J. Gastroenterol. 27(27), 4298\u20134321 (2021).","journal-title":"World J. Gastroenterol."},{"issue":"4","key":"51370_CR2","doi-asserted-by":"publisher","first-page":"e214708","DOI":"10.1001\/jamanetworkopen.2021.4708","volume":"4","author":"L Rahib","year":"2021","unstructured":"Rahib, L., Wehner, M. R., Matrisian, L. M. & Nead, K. T. Estimated projection of US Cancer Incidence and death to 2040. JAMA Netw. Open. 4(4), e214708 (2021).","journal-title":"JAMA Netw. Open."},{"issue":"1","key":"51370_CR3","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1053\/j.gastro.2020.02.068","volume":"159","author":"M Arnold","year":"2020","unstructured":"Arnold, M. et al. Global burden of 5 major types of gastrointestinal cancer. Gastroenterology 159(1), 335\u201349e15 (2020).","journal-title":"Gastroenterology"},{"issue":"2","key":"51370_CR4","doi-asserted-by":"publisher","first-page":"107064","DOI":"10.1016\/j.ejso.2023.107064","volume":"51","author":"M Qurashi","year":"2025","unstructured":"Qurashi, M., Vithayathil, M. & Khan, S. A. Epidemiology of cholangiocarcinoma. Eur. J. Surg. Oncol. 51(2), 107064 (2025).","journal-title":"Eur. J. Surg. Oncol."},{"key":"51370_CR5","first-page":"15","volume":"25","author":"TA Liu","year":"2024","unstructured":"Liu, T. A., Stewart, T. M. & Casero, R. A. Jr. The synergistic benefit of combination strategies targeting tumor cell polyamine homeostasis. Int. J. Mol. Sci. 25, 15 (2024).","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"51370_CR6","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1186\/s12967-022-03823-8","volume":"20","author":"CPK Patro","year":"2022","unstructured":"Patro, C. P. K. et al. MTAP loss: A possible therapeutic approach for glioblastoma. J. Transl Med. 20(1), 620 (2022).","journal-title":"J. Transl Med."},{"issue":"10","key":"51370_CR7","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1097\/PAS.0000000000002297","volume":"48","author":"N Gorbokon","year":"2024","unstructured":"Gorbokon, N. et al. Prevalence of S-methyl-5\u2019-thioadenosine phosphorylase (MTAP) deficiency in human cancer: A tissue microarray study on 13,067 tumors from 149 different tumor types. Am. J. Surg. Pathol. 48(10), 1245\u20131258 (2024).","journal-title":"Am. J. Surg. Pathol."},{"issue":"6278","key":"51370_CR8","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1126\/science.aad5214","volume":"351","author":"GV Kryukov","year":"2016","unstructured":"Kryukov, G. V. et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science 351(6278), 1214\u20131218 (2016).","journal-title":"Science"},{"issue":"11","key":"51370_CR9","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/s41568-018-0050-3","volume":"18","author":"RA Casero Jr","year":"2018","unstructured":"Casero, R. A. Jr., Murray Stewart, T. & Pegg, A. E. Polyamine metabolism and cancer: Treatments, challenges and opportunities. Nat. Rev. Cancer. 18(11), 681\u2013695 (2018).","journal-title":"Nat. Rev. Cancer"},{"issue":"5","key":"51370_CR10","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1158\/2767-9764.CRC-23-0450","volume":"4","author":"NK Tangudu","year":"2024","unstructured":"Tangudu, N. K. et al. De Novo purine metabolism is a metabolic vulnerability of cancers with low p16 expression. Cancer Res. Commun. 4(5), 1174\u20131188 (2024).","journal-title":"Cancer Res. Commun."},{"issue":"11","key":"51370_CR11","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1007\/s00018-015-1847-9","volume":"72","author":"N Stopa","year":"2015","unstructured":"Stopa, N., Krebs, J. E. & Shechter, D. The PRMT5 arginine methyltransferase: Many roles in development, cancer and beyond. Cell. Mol. Life Sci. 72(11), 2041\u20132059 (2015).","journal-title":"Cell. Mol. Life Sci."},{"issue":"53","key":"51370_CR12","doi-asserted-by":"publisher","first-page":"39653","DOI":"10.1039\/D4RA05497K","volume":"14","author":"M Hu","year":"2024","unstructured":"Hu, M. & Chen, X. A review of the known MTA-cooperative PRMT5 inhibitors. RSC Adv. 14(53), 39653\u201339691 (2024).","journal-title":"RSC Adv."},{"key":"51370_CR13","doi-asserted-by":"publisher","first-page":"1264785","DOI":"10.3389\/fonc.2023.1264785","volume":"13","author":"C Bray","year":"2023","unstructured":"Bray, C., Balcells, C., McNeish, I. A. & Keun, H. C. The potential and challenges of targeting MTAP-negative cancers beyond synthetic lethality. Front. Oncol. 13, 1264785 (2023).","journal-title":"Front. Oncol."},{"key":"51370_CR14","doi-asserted-by":"crossref","unstructured":"Vrugt, B. et al. Deletions of CDKN2A and MTAP detected by copy-number variation array are associated with loss of p16 and MTAP protein in pleural mesothelioma. Cancers (Basel) 15(20), 4978 (2023).","DOI":"10.3390\/cancers15204978"},{"issue":"11","key":"51370_CR15","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1038\/modpathol.2012.102","volume":"25","author":"HU Schildhaus","year":"2012","unstructured":"Schildhaus, H. U. et al. Definition of a fluorescence in-situ hybridization score identifies high- and low-level FGFR1 amplification types in squamous cell lung cancer. Mod. Pathol. 25(11), 1473\u20131480 (2012).","journal-title":"Mod. Pathol."},{"issue":"6","key":"51370_CR16","first-page":"3665","volume":"19","author":"V Moentenich","year":"2020","unstructured":"Moentenich, V. et al. Claudin 18.2 expression in esophageal adenocarcinoma and its potential impact on future treatment strategies. Oncol. Lett. 19(6), 3665\u20133670 (2020).","journal-title":"Oncol. Lett."},{"key":"51370_CR17","doi-asserted-by":"crossref","unstructured":"Loeser, H. et al. Y chromosome loss is a frequent event in Barrett\u2019s adenocarcinoma and associated with poor outcome. Cancers (Basel) 12(7), 1743 (2020).","DOI":"10.3390\/cancers12071743"},{"issue":"1","key":"51370_CR18","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12885-018-5242-4","volume":"19","author":"PS Plum","year":"2019","unstructured":"Plum, P. S. et al. HER2\/neu (ERBB2) expression and gene amplification correlates with better survival in esophageal adenocarcinoma. BMC Cancer. 19(1), 38 (2019).","journal-title":"BMC Cancer"},{"issue":"3","key":"51370_CR19","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1136\/jcp-2023-209341","volume":"78","author":"G Mauri","year":"2025","unstructured":"Mauri, G. et al. Clinicopathological characterisation of MTAP alterations in gastrointestinal cancers. J. Clin. Pathol. 78(3), 195\u2013201 (2025).","journal-title":"J. Clin. Pathol."},{"issue":"4_suppl","key":"51370_CR20","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1200\/JCO.2019.37.4_suppl.278","volume":"37","author":"A Doyle","year":"2019","unstructured":"Doyle, A. et al. The impact of CDKN2A mutations on overall survival in pancreatic adenocarcinoma. J. Clin. Oncol. 37(4_suppl), 278 (2019).","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"51370_CR21","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2217\/bmm-2017-0152","volume":"12","author":"LF Abrahao-Machado","year":"2018","unstructured":"Abrahao-Machado, L. F. et al. Loss of MTAP expression is a negative prognostic marker in Ewing sarcoma family of tumors. Biomark. Med. 12(1), 35\u201344 (2018).","journal-title":"Biomark. Med."},{"issue":"1","key":"51370_CR22","doi-asserted-by":"publisher","first-page":"e70012","DOI":"10.1002\/2056-4538.70012","volume":"11","author":"N Gorbokon","year":"2025","unstructured":"Gorbokon, N. et al. Loss of MTAP expression is strongly linked to homozygous 9p21 deletion, unfavorable tumor phenotype, and noninflamed microenvironment in urothelial bladder cancer. J. Pathol. Clin. Res. 11(1), e70012 (2025).","journal-title":"J. Pathol. Clin. Res."},{"issue":"9","key":"51370_CR23","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/j.ejso.2014.04.017","volume":"40","author":"CY Su","year":"2014","unstructured":"Su, C. Y. et al. MTAP is an independent prognosis marker and the concordant loss of MTAP and p16 expression predicts short survival in non-small cell lung cancer patients. Eur. J. Surg. Oncol. 40(9), 1143\u20131150 (2014).","journal-title":"Eur. J. Surg. Oncol."},{"issue":"6","key":"51370_CR24","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1093\/oncolo\/oyae011","volume":"29","author":"NYL Ngoi","year":"2024","unstructured":"Ngoi, N. Y. L. et al. Methylthioadenosine phosphorylase genomic loss in advanced gastrointestinal cancers. Oncologist 29(6), 493\u2013503 (2024).","journal-title":"Oncologist"},{"issue":"6","key":"51370_CR25","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1002\/gcc.20867","volume":"50","author":"J Kim","year":"2011","unstructured":"Kim, J. et al. Downregulation of methylthioadenosin phosphorylase by homozygous deletion in gastric carcinoma. Genes Chromosomes Cancer. 50(6), 421\u2013433 (2011).","journal-title":"Genes Chromosomes Cancer"},{"issue":"11","key":"51370_CR26","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1158\/2159-8290.CD-23-0669","volume":"13","author":"LD Engstrom","year":"2023","unstructured":"Engstrom, L. D. et al. MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP-deleted cancer. Cancer Discov. 13(11), 2412\u20132431 (2023).","journal-title":"Cancer Discov"},{"issue":"1","key":"51370_CR27","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.ccell.2019.05.014","volume":"36","author":"A Fedoriw","year":"2019","unstructured":"Fedoriw, A. et al. Anti-tumor activity of the type I PRMT inhibitor, GSK3368715, synergizes with PRMT5 inhibition through MTAP loss. Cancer Cell. 36(1), 100\u2013114 (2019).","journal-title":"Cancer Cell."},{"issue":"8","key":"51370_CR28","doi-asserted-by":"publisher","first-page":"6064","DOI":"10.1021\/acs.jmedchem.4c00133","volume":"67","author":"KM Cottrell","year":"2024","unstructured":"Cottrell, K. M. et al. Discovery of TNG908: A selective, brain penetrant, MTA-cooperative PRMT5 inhibitor that is synthetically lethal with MTAP-deleted cancers. J. Med. Chem. 67(8), 6064\u20136080 (2024).","journal-title":"J. Med. Chem."},{"issue":"12","key":"51370_CR29","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1016\/j.annonc.2024.08.2339","volume":"35","author":"J Rodon","year":"2024","unstructured":"Rodon, J. et al. First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: Results from phase I dose exploration. Ann. Oncol. 35(12), 1138\u20131147 (2024).","journal-title":"Ann. Oncol."},{"issue":"18","key":"51370_CR30","doi-asserted-by":"publisher","first-page":"3592","DOI":"10.1158\/1078-0432.CCR-23-0092","volume":"29","author":"M Vieito","year":"2023","unstructured":"Vieito, M. et al. Phase 1 study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in advanced solid tumors. Clin. Cancer Res. 29(18), 3592\u20133602 (2023).","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"51370_CR31","doi-asserted-by":"publisher","first-page":"102961","DOI":"10.1016\/j.esmoop.2024.102961","volume":"9","author":"J Rodon","year":"2024","unstructured":"Rodon, J. et al. A phase I study to evaluate the safety, pharmacokinetics, and pharmacodynamics of PF-06939999 (PRMT5 inhibitor) in patients with selected advanced or metastatic tumors with high incidence of splicing factor gene mutations. ESMO Open. 9(4), 102961 (2024).","journal-title":"ESMO Open."},{"issue":"1","key":"51370_CR32","doi-asserted-by":"publisher","first-page":"4228","DOI":"10.1038\/s41467-021-24240-3","volume":"12","author":"Y Barekatain","year":"2021","unstructured":"Barekatain, Y. et al. Homozygous MTAP deletion in primary human glioblastoma is not associated with elevation of methylthioadenosine. Nat. Commun. 12(1), 4228 (2021).","journal-title":"Nat. Commun."},{"key":"51370_CR33","doi-asserted-by":"publisher","first-page":"107963","DOI":"10.1016\/j.lungcan.2024.107963","volume":"197","author":"MM Brune","year":"2024","unstructured":"Brune, M. M. et al. MTAP as an emerging biomarker in thoracic malignancies. Lung Cancer. 197, 107963 (2024).","journal-title":"Lung Cancer"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-51370-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-51370-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-51370-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T16:13:25Z","timestamp":1778688805000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-51370-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,13]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["51370"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-51370-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,13]]},"assertion":[{"value":"25 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of the University of Cologne (protocol code 16\u2013230 and 21-1146). Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and informed consent"}}],"article-number":"15061"}}